Baxter International (BAX) official guidance

We continue to expect our diluted share count to average approximately 518 million shares for the year.

We expect our diluted share count to average approximately 518 million shares for the year.

We expect our diluted share count to average approximately 518 million shares for the year.

We continue to anticipate our full-year tax rate to range between 18.5% and 19.5%.

On a Continuing Operations basis, we anticipate a full year tax rate to range between 18.5% and 19.5%.

On a continuing operations basis, we anticipate a full-year tax rate to range between 18.5%-19.5%.

In addition, reported sales are expected to include a headwind of approximately $25 million from MSA revenues from Vantive, representing approximately 30 basis points of impact on reported growth.

In addition, reported sales are expected to include a headwind of approximately $25 million from MSA revenues from Vantive, representing approximately 30 basis points of impact on reported growth.

In addition, reported sales are expected to include a headwind of approximately $25 million from MSA revenues from Vantive.

There is still significant work ahead, but the strides we have made in the first half give us increased confidence in our ability to achieve our net leverage target of approximately 3X by the end of the year.

Given our year-to-date business challenges, we now expect to achieve our 3x net leverage target by the end of 2026.

We now expect our non-operating expenses, which include net interest expense and other income and expense, to total between $260 million-$280 million.

We expect our non-operating expenses, which include net interest expense and other income and expense, to total between $280 million-$300 million, reflecting higher interest expense and a lower contribution from other income.

We expect our non-operating expenses, which include net interest expense and other income and expense, to total between $280 million-$300 million.

We continue to expect full-year adjusted operating margin to range between 13%-14%.

We continue to expect full year adjusted operating margin from Continuing Operations to range between 13%-14%.

We expect full-year adjusted operating margin from continuing operations to range between 13% and 14%.

In HST, we continue to expect full year organic sales to grow low single digits, supported by anticipated contributions from both the CCS and Front Line Care divisions.

In HST, we continue to expect full year organic sales to grow low single digits, supported by anticipated contributions from both the Care and Connectivity Solutions and Front Line Care divisions.

In HST, we expect full-year organic sales to grow low single digits.

As it relates to the segments, in MPT, we now expect full year organic sales to grow low single digits.

In MPT, we expect full year organic sales to be flat to slightly up.

As it relates to the segments, in MPT, we expect full-year organic sales to be flat to slightly up.

Excluding the impact of foreign exchange and MSA revenues, we now expect organic sales growth of 2%-3% for 2026.

Excluding the impact of foreign currency and MSA revenues, we expect approximately flat organic sales growth for 2026.

Excluding the impact of foreign exchange and MSA revenues, we expect organic sales growth of approximately flat for 2026.

For the full year, we now expect total sales growth to be 3%-4% on a reported basis.

For the full year, we continue to expect total sales growth to be flat to 1% growth on a reported basis.

For full year 2026, we expect total sales growth to be flat to 1% growth on a reported basis.

TSA income and other reimbursements is now expected to range between $155 million-$165 million.

TSA income and other reimbursements are expected to range from $130 million-$140 million.

Given the tariff refund in the quarter, we are raising our full-year adjusted earnings from $1.85-$2.05 per diluted share to $1.95-$2.15 per share.

•Adjusted earnings from continuing operations per diluted share: $1.95 to $2.15 (previously $1.85 to $2.05)

Based on all these factors, we continue to expect full year adjusted earnings on a Continuing Operations basis of $1.85-$2.05 per diluted share.

| Adjusted diluted EPS | $1.85 - $2.05 |

Based on all these factors, we now anticipate full-year adjusted earnings on a continuing operations basis of $1.85-$2.05 per diluted share.

| Adjusted diluted EPS | $1.85 - $2.05 |

•Organic sales growth from continuing operations: 2% to 3% (previously approximately flat)

•Organic sales growth from continuing operations: approximately flat

| Organic sales growth | ~ Flat |

•Reported sales growth from continuing operations: 3% to 4% (previously flat to 1%)

| Sales growth - U.S. GAAP | Flat - 1% |

| Sales growth - U.S. GAAP | Flat - 1% |

With respect to free cash flow, we continue to expect free cash flow to be back half weighted consistent with 2025.

We do expect in 2026 that free cash flow will improve versus 2025, driven primarily by, by stronger working capital performance and, as well, obviously, we, you know, don't expect to repeat some of the one-time hits that happened in 2025, specifically the, expenses for the hurricane.

Taken together, we continue to expect a second half improvement in organic sales growth, operating margin, and adjusted earnings.